02627 中慧生物－Ｂ
AB&B BIO-TECH-B
AB&B BIO-TECH-B
| Register Close | 2025/08/05 IPO Closing in 4 Days |
| Listing Date | 2025/08/08 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Ab&B Bio-Tech CO was founded in 2015, it is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods.
--
As of July 21, 2025, the Group had two Core Products, the quadrivalent subunit influenza vaccine, and lyophilized (freeze-dried) human rabies vaccine candidate, and 11 other vaccine candidates covering various disease areas with considerable needs for vaccination.
--
The Group’s quadrivalent subunit influenza vaccine received NDA approval from the NMPA in May 2023 for use in individuals aged three years and above under the brand name Huierkangxin. It was the first and only quadrivalent subunit influenza vaccine approved in China as of July 18, 2025.
--
The Group generated all of its revenue from the sales of its quadrivalent subunit influenza vaccines. The Group’s customers were district- or county-level CDCs.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 33.44M H shares |
| No. of International Offer Shares | 30.10M H shares |
| No. of HK Offer Shares | 3.34M H shares |
| Offer Price | $12.90 - $15.50 |
| Stock Code | 2627 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited, CMB International Capital Limited |
| Underwriter(s) | CLSA Limited, CMB International Capital Limited, Livermore Holdings Limited, Funde Securities Limited, Aristo Securities Limited, BOCI Asia Limited, ICBC International Securities Limited |
TIME TABLE
| Application Period | Jul 31 (Thu) - noon, Aug 05 (Tue) |
| Price Determination Date | Aug 05 (Tue) |
| Result Announcement Date | On or before Aug 07 (Thu) |
| Result Announcement Date | On or before Aug 07 (Thu) |
| Result Announcement Date | On or before Aug 08 (Fri) |
| Dealings in Shares commence on | Aug 08, 2025. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $12.90 - $15.50 |
| Capitalization | 5.08B - 6.10B |
| NAV / share ($) | $1.11 - $1.32 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 14.2, the net proceeds raised would be HKD 420.50M, of which |
| 63.6% : Development and domestic and international registration of Core Products |
| 18.1% : Development and registration of other vaccine candidates |
| 8.4% : Enhancement of manufacturing and commercialization capabilities |
| 4.9% : Development of technology platforms |
| 5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).